



## Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase

**Liege, Belgium, 05 August 2020 – 17:45 CEST** –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the "**Company**" or "**Mithra**") announces the below information, following the issuance of 159,800 new shares today for a total amount of EUR 3,104,869 following the First Put Option Notice issued on May 29 2020<sup>1</sup> in the framework of the formal completion of the Company's capital increase approved by the Board on May 22, 2020 according to the terms of the LDA capital commitment agreement<sup>2</sup>.

Following this capital increase's completion, Mithra now has 42,714,097 outstanding shares carrying voting rights (42,554,297 outstanding shares carrying voting rights previously).

Therefore, Mithra publishes the following updated information:

- Share capital: EUR 31,270,872.40
- Total number of securities carrying voting rights: 42,714,097 (all ordinary shares)
- Total number of voting rights (= denominator): 42,714,097 (all relating to ordinary shares)
- Number of outstanding rights to subscribe to securities carrying voting rights:
  - Pursuant to the share option plan of 2 March 2015: 620 subscription rights giving right to 1,023,000 ordinary shares
  - Pursuant to the share option plan of 5 November 2018: 1,307,205 subscription rights giving right to 1,307,205 ordinary shares
  - Pursuant to the share option plan of 22 July 2020 : 690,000 subscription rights giving right to 690,000 ordinary shares

\*\*\*\*\*

### For more information, please contact:

**Alexandra Deschner (IRO)** : +32 490 58 35 23 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

**Carole Kousis (Press)** : +32 349 28 22 - [press@mithra.com](mailto:press@mithra.com)

---

<sup>1</sup> [Mithra Press release](#), 05/06/2020

<sup>2</sup> [Mithra Press release](#), 24/04/2020

## About Mithra

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment targeting perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)*

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

---



News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)